This is a multicenter, randomized, double blind, double-dummy and controlled clinical trial
aimed to compare the clinical efficacy and safety of Kunxian Capsule, a compound of Chinese
traditional medicine, and the active comparator,Methotrexate for the treatment of rheumatoid
arthritis. The primary end-point is that Kunxian Capsule is not inferior to Methotrexate both
in efficacy and safety.
Phase:
Phase 4
Details
Lead Sponsor:
Chinese SLE Treatment And Research Group
Collaborators:
CHENLIJI Pharmaceutical Company,Guangzhou Pharmaceutical Group CHINESE RHEUMATISM DATA CENTER